CLINICAL TRIALS PROFILE FOR LAROTRECTINIB
✉ Email this page to a colleague
All Clinical Trials for Larotrectinib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02122913 ↗ | A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer | Completed | Bayer | Phase 1 | 2014-05-04 | This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also investigates how the drug is absorbed and processed in the human body. This is the first study to test larotrectinib in humans with cancer, for whom no other effective therapy exists. |
| NCT02122913 ↗ | A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer | Completed | Loxo Oncology, Inc. | Phase 1 | 2014-05-04 | This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also investigates how the drug is absorbed and processed in the human body. This is the first study to test larotrectinib in humans with cancer, for whom no other effective therapy exists. |
| NCT02465060 ↗ | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2015-08-12 | This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma. |
| NCT02576431 ↗ | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Recruiting | Bayer | Phase 2 | 2015-09-30 | This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Larotrectinib
Condition Name
| Condition Name for Larotrectinib | |
| Intervention | Trials |
| Solid Tumors Harboring NTRK Fusion | 3 |
| Advanced Malignant Solid Neoplasm | 3 |
| Recurrent Malignant Solid Neoplasm | 3 |
| Refractory Malignant Solid Neoplasm | 3 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Larotrectinib
Trials by Country
Clinical Trial Progress for Larotrectinib
Clinical Trial Phase
Clinical Trial Sponsors for Larotrectinib
Sponsor Name
